Expands U.S. therapeutic manufacturing capacity and creates the first transatlantic CDMO platform with a proven commercial track record in radioligand therapies WALTHAM, Mass., Nov. 9, 2026 /PRNewswire/ — PharmaLogic Holdings Corp. (“PharmaLogic” or the “Company”), the only independent contract development and manufacturing organization (CDMO) of scale dedicated exclusively to radiopharmaceuticals, today announced a definitive agreement … Contin…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.